Generate a tailored SOP for Dr. Mamoun Alhamadsheh. Improve your application with a focused, well-structured draft.
Mamoun Alhamadsheh is a professor of pharmaceutical chemistry at the University of the Pacific and a scientific co-founder of Eidos Therapeutics. His research primarily focuses on developing novel therapeutic agents for diseases related to transthyretin cardiac amyloidosis. Dr. Alhamadsheh's group discovered Acoramidis (formerly AG10), a transthyretin stabilizer that is currently in Phase 3 clinical trials. He actively advises Eidos Therapeutics on its scientific direction and is dedicated to advancing innovative technologies to improve drug delivery. He has received the New Investigator Award from the American Association of Colleges of Pharmacy and holds multiple patents and publications. His research is funded by grants from the National Institutes of Health. Dr. Alhamadsheh earned his Bachelor of Pharmacy from the Jordan University of Science and Technology and his PhD in medicinal chemistry from the University of Toledo, followed by postdoctoral research in chemical biology at Stanford University.
This is the PharmD professional program administered by the Thomas J. Long School of Pharmacy.